fbpx
Wikipedia

Cabozantinib

April 11, 2024

Cabozantinib, sold under the brand names Cometriq and Cabometyx among others, is an anti-cancer medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.[8][9] It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET.[7][6] It was discovered and developed by Exelixis Inc.

Cabozantinib
Clinical data
Trade namesCometriq, Cabometyx, others
Other namesXL184, BMS907351, cabozantinib s-malate
AHFS/Drugs.comMonograph
MedlinePlusa613015
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding≥99.7%
MetabolismLiver (CYP3A4-mediated)
Elimination half-life110 hours
ExcretionFeces (54%), urine (27%)
Identifiers
  • N-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
CAS Number
  • 849217-68-1
  • as salt: 1140909-48-3
PubChem CID
  • 25102847
DrugBank
  • DB08875
  • as salt: DBSALT001762
ChemSpider
  • 25948202
  • as salt: 25948203
UNII
  • 1C39JW444G
  • as salt: DR7ST46X58
KEGG
  • D10062
  • as salt: D10095
ChEBI
  • CHEBI:72317
  • as salt: CHEBI:72319
ChEMBL
  • ChEMBL2105717
  • as salt: ChEMBL2103868
CompTox Dashboard (EPA)
  • DTXSID10233968
ECHA InfoCard100.221.147
Chemical and physical data
FormulaC28H24FN3O5
Molar mass501.514 g·mol−1
3D model (JSmol)
  • Interactive image
  • COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC
  • InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)
  • Key:ONIQOQHATWINJY-UHFFFAOYSA-N

In November 2012, cabozantinib in its capsule formulation was approved by the US Food and Drug Administration (FDA) under the name Cometriq for treating people with medullary thyroid cancer.[12][13] The capsule form was approved in the European Union for the same purpose in 2014.[10] In April 2016, the FDA granted approval for marketing the tablet formulation (Cabometyx) as a second line treatment for kidney cancer[14][15] and the same was approved in the European Union in September of that year.[11] The brands Cometriq and Cabometyx have different formulations and are not interchangeable.[16]

Medical uses edit

Cabozantinib is used in two forms. A capsule form (Cometriq) is used to treat medullary thyroid cancer[9][7] and a tablet form (Cabometyx) is used to treat renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid carcinoma.[8][6][17]

Contraindications edit

Cabozantinib has not been tested in pregnant women; it causes harm to fetuses in rodents. Pregnant women should not take this drug, and women should not become pregnant while taking it. It is not known if cabozantinib is excreted in breast milk.[7][6]

Adverse effects edit

In the US, the capsule formulation (Cometriq) carries a black box warning of the risk of holes forming in the stomach or intestines as well as formation of fistulas (tunnels between the GI tract and the skin).[9] The black box also warns against the risk of uncontrolled bleeding.[9] The tablet formulation (Cabometyx) warns of these effects as well.[8][6]

The labels also warn of the risk of clots forming and causing heart attacks or strokes, high blood pressure including hypertensive crisis, osteonecrosis of the jaw, severe diarrhea, skin sloughing off the palms and soles, a syndrome with headaches, confusion, loss of vision, and seizures, and protein appearing in urine.[9][8][7][6]

Very common adverse effects (greater than 10% of people) include decreased appetite; low calcium, potassium, phosphate, and magnesium levels; high bilirubin levels; distorted sense of taste, headache, and dizziness; high blood pressure; distorted sense of hearing, earaches and sore throat; diarrhea, nausea, constipation, vomiting, stomach pain and upset stomach, and inflammation of the mouth and lips and a burning sensation in the mouth; skin sloughing off the palms and soles, hair color changes and hair loss, rash, dry skin, and red skin; joint pain and muscle spasms; fatigue and weakness; weight loss, elevated transaminases, higher cholesterol levels, and loss of red and white blood cells.[6]

Common adverse effects (between 1% and 10% of people) include abscesses (inside the body, on the skin, and in teeth skin), pneumonia, inflamed hair follicles, fungal infections, low thyroid levels, dehydration, loss of albumin, anxiety, depression, and confusion, peripheral neuropathy, tingling, and tremor, tinnitus, atrial fibrillation, low blood pressure, blocked veins, paleness, chills, fistulas forming in the trachea and esophagus, blood clots in the lungs, and bleeding in the respiratory tract, GI perforation, bleeding in the stomach and intestines, pancreatitis, hemorrhoids, anal fissure, anal inflammation, gallstones, hard skin growths, acne, blisters, abnormal hair growth, loss of skin color and skin flaking, chest pain, blood or protein in urine, wounds that don't heal well, and facial swelling.[6]

Interactions edit

Cabozantinib is a substrate of CYP3A4 and multidrug resistance-associated protein 2; drugs that inhibit these enzymes will increase the half-life of cabozantinib and potentially increase its adverse effects; drugs that activate them may cause cabozantinib to be less effective.[6]

Pharmacology edit

Cabozantinib inhibits the following receptor tyrosine kinases: MET (hepatocyte growth factor receptor protein) and VEGFR, RET, GAS6 receptor (AXL), KIT), and Fms-like tyrosine kinase-3 (FLT3).[6][18]

History edit

Cabozantinib was granted orphan drug status by the US Food and Drug Administration (FDA) in November 2010,[19] and in February 2017.[20]

Exelixis filed a new drug application with the FDA in 2012,[21] and in November 2012, cabozantinib in its capsule formulation was granted marketing approval by the FDA under the name Cometriq for treating people with medullary thyroid cancer.[12][13] The capsule form was approved in the European Union for the same purpose in 2014.[10]

In March 2016, Exelixis licensed to Ipsen worldwide rights (outside the US, Canada, and Japan) to market cabozantinib.[22]

In April 2016, the FDA granted approval for marketing the tablet formulation as a second line treatment for kidney cancer[14][15] and the same was approved in the European Union in September of that year.[11]

In December 2017, the FDA granted approval to cabozantinib (Cabometyx, Exelixis, Inc.) for the treatment of people with advanced renal cell carcinoma (RCC).[16] The approval was based on data from CABOSUN (NCT01835158), a randomized, open-label phase II multicenter study in 157 participants with intermediate and poor-risk previously untreated RCC.[16]

In January 2019, the FDA approved cabozantinib (Cabometyx, Exelixis, Inc.) for people with hepatocellular carcinoma who have been previously treated with sorafenib.[23] The approval was based on CELESTIAL (NCT01908426), a randomized (2:1), double-blind, placebo-controlled, multicenter trial in participants with hepatocellular carcinoma who had previously received sorafenib and had Child Pugh Class A liver impairment.

Research edit

Cabozantinib is being researched[24] for efficacy as a treatment for renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), cervical cancer, colorectal cancer (CRC), urothelial cancer, prostate cancer, gastric and gastroesophageal cancer, bladder cancer, melanoma, merkel cell carcinoma, brain cancers (including glioblastoma multiforme and anaplastic astrocytoma), non-small cell lung cancer (NSCLC), adrenocortical carcinoma, various sarcomas, head and neck squamous cell carcinomas (HNSCC), breast cancer, endometrial cancer, neuroendocrine cancers, and neurofibromatosis type 1.[25]

References edit

  1. ^ "Cabozantinib Use During Pregnancy". Drugs.com. 30 March 2020. Retrieved 23 September 2020.
  2. ^ "Cabometyx (Ipsen Pty Ltd)". Therapeutic Goods Administration (TGA). 13 January 2023. Retrieved 9 April 2023.
  3. ^ "Cabometyx cabozantinib (as (S)-malate) 20 mg film-coated tablet bottle (283800)". Therapeutic Goods Administration (TGA). 27 May 2022. Retrieved 9 April 2023.
  4. ^ "AusPAR: Cabozantinib". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
  5. ^ "Summary Basis of Decision (SBD) for Cabometyx". Health Canada. 23 October 2014. Retrieved 29 May 2022.
  6. ^ a b c d e f g h i j "Cabometyx 20mg, 40mg, 60mg - Summary of Product Characteristics (SmPC)". (emc). 7 October 2022. Retrieved 9 April 2023.
  7. ^ a b c d e "Cometriq 20 & 80 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 6 October 2022. Retrieved 9 April 2023.
  8. ^ a b c d e "Cabometyx- cabozantinib tablet". DailyMed. 21 July 2020. Retrieved 23 September 2020.
  9. ^ a b c d e f "Cometriq- cabozantinib kit Cometriq- cabozantinib capsule". DailyMed. 11 February 2020. Retrieved 23 September 2020.
  10. ^ a b c "Cometriq EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 23 September 2020.
  11. ^ a b c "Cabometyx EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 23 September 2020.
  12. ^ a b (Press release). U.S. Food and Drug Administration (FDA). 29 November 2012. Archived from the original on July 7, 2014.
  13. ^ a b "Drug Approval Package: Cometriq (cabozantinib) Capsules NDA #203756". U.S. Food and Drug Administration (FDA). Retrieved 23 September 2020.
  14. ^ a b "Cabozantinib (Cabometyx)". U.S. Food and Drug Administration (FDA). 25 April 2016. Retrieved 23 September 2020.
  15. ^ a b "Cabometyx (cabozantinib) Tablets". U.S. Food and Drug Administration (FDA). 12 January 2018. Retrieved 23 September 2020.
  16. ^ a b c "FDA grants regular approval to Cabometyx for first-line treatment of a". U.S. Food and Drug Administration (FDA). 19 December 2017. Retrieved 23 September 2020.   This article incorporates text from this source, which is in the public domain.
  17. ^ "FDA approves cabozantinib for differentiated thyroid cancer". U.S. Food and Drug Administration (FDA). 22 September 2021. Retrieved 22 September 2021.   This article incorporates text from this source, which is in the public domain.
  18. ^ Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, et al. (December 2011). "Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth". Molecular Cancer Therapeutics. 10 (12): 2298–2308. doi:10.1158/1535-7163.MCT-11-0264. PMID 21926191. S2CID 16709393.
  19. ^ "Cabozantinib Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 29 November 2010. Retrieved 11 November 2020.
  20. ^ "Search Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 2 March 2017. Retrieved 11 November 2020.
  21. ^ . Archived from the original on 2012-04-02. Retrieved 24 October 2011.
  22. ^ Garde D (March 1, 2016). "Ipsen bets up to $855M on Exelixis' once-failed cancer drug". FierceBiotech.
  23. ^ "FDA approves cabozantinib for hepatocellular carcinoma". U.S. Food and Drug Administration (FDA). 14 January 2019. Retrieved 23 September 2020.   This article incorporates text from this source, which is in the public domain.
  24. ^ "Search of: cabozantinib | Recruiting, Active, not recruiting, Enrolling by invitation Studies - List Results - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2021-08-09.
  25. ^ Fisher MJ, Shih CS, Rhodes SD, Armstrong AE, Wolters PL, Dombi E, et al. (January 2021). "Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial". Nature Medicine. 27 (1): 165–173. doi:10.1038/s41591-020-01193-6. PMC 8275010. PMID 33442015.

Further reading edit

  • Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, et al. (November 2015). "Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma". The New England Journal of Medicine. 373 (19): 1814–1823. doi:10.1056/nejmoa1510016. PMC 5024539. PMID 26406150.

External links edit

  • "Cabozantinib s-malate". NCI Drug Dictionary. National Cancer Institute.
  • "Cabozantinib-S-Malate". National Cancer Institute. 19 December 2012.
  • "Cabozantinib (liver and kidney cancer)". MedlinePlus.
  • Clinical trial number NCT01835158 for "Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer" at ClinicalTrials.gov
  • Clinical trial number NCT01908426 for "Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL)" at ClinicalTrials.gov
  • Clinical trial number NCT03690388 for "A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy" at ClinicalTrials.gov

April 11, 2024
cabozantinib, sold, under, brand, names, cometriq, cabometyx, among, others, anti, cancer, medication, used, treat, medullary, thyroid, cancer, renal, cell, carcinoma, hepatocellular, carcinoma, small, molecule, inhibitor, tyrosine, kinases, vegfr2, also, inhi. Cabozantinib sold under the brand names Cometriq and Cabometyx among others is an anti cancer medication used to treat medullary thyroid cancer renal cell carcinoma and hepatocellular carcinoma 8 9 It is a small molecule inhibitor of the tyrosine kinases c Met and VEGFR2 and also inhibits AXL and RET 7 6 It was discovered and developed by Exelixis Inc CabozantinibClinical dataTrade namesCometriq Cabometyx othersOther namesXL184 BMS907351 cabozantinib s malateAHFS Drugs comMonographMedlinePlusa613015License dataEU EMA by INN US DailyMed Cabozantinib US FDA CabozantinibPregnancycategoryAU D 1 Routes ofadministrationBy mouthATC codeL01EX07 WHO Legal statusLegal statusAU S4 Prescription only 2 3 4 CA only 5 UK POM Prescription only 6 7 US only 8 9 EU Rx only 10 11 Pharmacokinetic dataProtein binding 99 7 MetabolismLiver CYP3A4 mediated Elimination half life110 hoursExcretionFeces 54 urine 27 IdentifiersIUPAC name N 4 6 7 Dimethoxyquinolin 4 yl oxy phenyl N 4 fluorophenyl cyclopropane 1 1 dicarboxamideCAS Number849217 68 1as salt 1140909 48 3PubChem CID25102847DrugBankDB08875as salt DBSALT001762ChemSpider25948202as salt 25948203UNII1C39JW444Gas salt DR7ST46X58KEGGD10062as salt D10095ChEBICHEBI 72317as salt CHEBI 72319ChEMBLChEMBL2105717as salt ChEMBL2103868CompTox Dashboard EPA DTXSID10233968ECHA InfoCard100 221 147Chemical and physical dataFormulaC 28H 24F N 3O 5Molar mass501 514 g mol 13D model JSmol Interactive imageSMILES COc1cc2nccc Oc3ccc NC O C4 C O Nc5ccc F cc5 CC4 cc3 c2cc1OCInChI InChI 1S C28H24FN3O5 c1 35 24 15 21 22 16 25 24 36 2 30 14 11 23 21 37 20 9 7 19 8 10 20 32 27 34 28 12 13 28 26 33 31 18 5 3 17 29 4 6 18 h3 11 14 16H 12 13H2 1 2H3 H 31 33 H 32 34 Key ONIQOQHATWINJY UHFFFAOYSA NIn November 2012 cabozantinib in its capsule formulation was approved by the US Food and Drug Administration FDA under the name Cometriq for treating people with medullary thyroid cancer 12 13 The capsule form was approved in the European Union for the same purpose in 2014 10 In April 2016 the FDA granted approval for marketing the tablet formulation Cabometyx as a second line treatment for kidney cancer 14 15 and the same was approved in the European Union in September of that year 11 The brands Cometriq and Cabometyx have different formulations and are not interchangeable 16 Contents 1 Medical uses 2 Contraindications 3 Adverse effects 4 Interactions 5 Pharmacology 6 History 7 Research 8 References 9 Further reading 10 External linksMedical uses editCabozantinib is used in two forms A capsule form Cometriq is used to treat medullary thyroid cancer 9 7 and a tablet form Cabometyx is used to treat renal cell carcinoma hepatocellular carcinoma and differentiated thyroid carcinoma 8 6 17 Contraindications editCabozantinib has not been tested in pregnant women it causes harm to fetuses in rodents Pregnant women should not take this drug and women should not become pregnant while taking it It is not known if cabozantinib is excreted in breast milk 7 6 Adverse effects editIn the US the capsule formulation Cometriq carries a black box warning of the risk of holes forming in the stomach or intestines as well as formation of fistulas tunnels between the GI tract and the skin 9 The black box also warns against the risk of uncontrolled bleeding 9 The tablet formulation Cabometyx warns of these effects as well 8 6 The labels also warn of the risk of clots forming and causing heart attacks or strokes high blood pressure including hypertensive crisis osteonecrosis of the jaw severe diarrhea skin sloughing off the palms and soles a syndrome with headaches confusion loss of vision and seizures and protein appearing in urine 9 8 7 6 Very common adverse effects greater than 10 of people include decreased appetite low calcium potassium phosphate and magnesium levels high bilirubin levels distorted sense of taste headache and dizziness high blood pressure distorted sense of hearing earaches and sore throat diarrhea nausea constipation vomiting stomach pain and upset stomach and inflammation of the mouth and lips and a burning sensation in the mouth skin sloughing off the palms and soles hair color changes and hair loss rash dry skin and red skin joint pain and muscle spasms fatigue and weakness weight loss elevated transaminases higher cholesterol levels and loss of red and white blood cells 6 Common adverse effects between 1 and 10 of people include abscesses inside the body on the skin and in teeth skin pneumonia inflamed hair follicles fungal infections low thyroid levels dehydration loss of albumin anxiety depression and confusion peripheral neuropathy tingling and tremor tinnitus atrial fibrillation low blood pressure blocked veins paleness chills fistulas forming in the trachea and esophagus blood clots in the lungs and bleeding in the respiratory tract GI perforation bleeding in the stomach and intestines pancreatitis hemorrhoids anal fissure anal inflammation gallstones hard skin growths acne blisters abnormal hair growth loss of skin color and skin flaking chest pain blood or protein in urine wounds that don t heal well and facial swelling 6 Interactions editCabozantinib is a substrate of CYP3A4 and multidrug resistance associated protein 2 drugs that inhibit these enzymes will increase the half life of cabozantinib and potentially increase its adverse effects drugs that activate them may cause cabozantinib to be less effective 6 Pharmacology editCabozantinib inhibits the following receptor tyrosine kinases MET hepatocyte growth factor receptor protein and VEGFR RET GAS6 receptor AXL KIT and Fms like tyrosine kinase 3 FLT3 6 18 History editCabozantinib was granted orphan drug status by the US Food and Drug Administration FDA in November 2010 19 and in February 2017 20 Exelixis filed a new drug application with the FDA in 2012 21 and in November 2012 cabozantinib in its capsule formulation was granted marketing approval by the FDA under the name Cometriq for treating people with medullary thyroid cancer 12 13 The capsule form was approved in the European Union for the same purpose in 2014 10 In March 2016 Exelixis licensed to Ipsen worldwide rights outside the US Canada and Japan to market cabozantinib 22 In April 2016 the FDA granted approval for marketing the tablet formulation as a second line treatment for kidney cancer 14 15 and the same was approved in the European Union in September of that year 11 In December 2017 the FDA granted approval to cabozantinib Cabometyx Exelixis Inc for the treatment of people with advanced renal cell carcinoma RCC 16 The approval was based on data from CABOSUN NCT01835158 a randomized open label phase II multicenter study in 157 participants with intermediate and poor risk previously untreated RCC 16 In January 2019 the FDA approved cabozantinib Cabometyx Exelixis Inc for people with hepatocellular carcinoma who have been previously treated with sorafenib 23 The approval was based on CELESTIAL NCT01908426 a randomized 2 1 double blind placebo controlled multicenter trial in participants with hepatocellular carcinoma who had previously received sorafenib and had Child Pugh Class A liver impairment Research editCabozantinib is being researched 24 for efficacy as a treatment for renal cell carcinoma RCC hepatocellular carcinoma HCC cervical cancer colorectal cancer CRC urothelial cancer prostate cancer gastric and gastroesophageal cancer bladder cancer melanoma merkel cell carcinoma brain cancers including glioblastoma multiforme and anaplastic astrocytoma non small cell lung cancer NSCLC adrenocortical carcinoma various sarcomas head and neck squamous cell carcinomas HNSCC breast cancer endometrial cancer neuroendocrine cancers and neurofibromatosis type 1 25 References edit Cabozantinib Use During Pregnancy Drugs com 30 March 2020 Retrieved 23 September 2020 Cabometyx Ipsen Pty Ltd Therapeutic Goods Administration TGA 13 January 2023 Retrieved 9 April 2023 Cabometyx cabozantinib as S malate 20 mg film coated tablet bottle 283800 Therapeutic Goods Administration TGA 27 May 2022 Retrieved 9 April 2023 AusPAR Cabozantinib Therapeutic Goods Administration TGA 21 June 2022 Retrieved 9 April 2023 Summary Basis of Decision SBD for Cabometyx Health Canada 23 October 2014 Retrieved 29 May 2022 a b c d e f g h i j Cabometyx 20mg 40mg 60mg Summary of Product Characteristics SmPC emc 7 October 2022 Retrieved 9 April 2023 a b c d e Cometriq 20 amp 80 mg hard capsules Summary of Product Characteristics SmPC emc 6 October 2022 Retrieved 9 April 2023 a b c d e Cabometyx cabozantinib tablet DailyMed 21 July 2020 Retrieved 23 September 2020 a b c d e f Cometriq cabozantinib kit Cometriq cabozantinib capsule DailyMed 11 February 2020 Retrieved 23 September 2020 a b c Cometriq EPAR European Medicines Agency EMA 17 September 2018 Retrieved 23 September 2020 a b c Cabometyx EPAR European Medicines Agency EMA 17 September 2018 Retrieved 23 September 2020 a b FDA approves Cometriq to treat rare type of thyroid cancer Press release U S Food and Drug Administration FDA 29 November 2012 Archived from the original on July 7 2014 a b Drug Approval Package Cometriq cabozantinib Capsules NDA 203756 U S Food and Drug Administration FDA Retrieved 23 September 2020 a b Cabozantinib Cabometyx U S Food and Drug Administration FDA 25 April 2016 Retrieved 23 September 2020 a b Cabometyx cabozantinib Tablets U S Food and Drug Administration FDA 12 January 2018 Retrieved 23 September 2020 a b c FDA grants regular approval to Cabometyx for first line treatment of a U S Food and Drug Administration FDA 19 December 2017 Retrieved 23 September 2020 nbsp This article incorporates text from this source which is in the public domain FDA approves cabozantinib for differentiated thyroid cancer U S Food and Drug Administration FDA 22 September 2021 Retrieved 22 September 2021 nbsp This article incorporates text from this source which is in the public domain Yakes FM Chen J Tan J Yamaguchi K Shi Y Yu P et al December 2011 Cabozantinib XL184 a novel MET and VEGFR2 inhibitor simultaneously suppresses metastasis angiogenesis and tumor growth Molecular Cancer Therapeutics 10 12 2298 2308 doi 10 1158 1535 7163 MCT 11 0264 PMID 21926191 S2CID 16709393 Cabozantinib Orphan Drug Designations and Approvals U S Food and Drug Administration FDA 29 November 2010 Retrieved 11 November 2020 Search Orphan Drug Designations and Approvals U S Food and Drug Administration FDA 2 March 2017 Retrieved 11 November 2020 Thyroid cancer drug cabozantinib prolongs PFS Archived from the original on 2012 04 02 Retrieved 24 October 2011 Garde D March 1 2016 Ipsen bets up to 855M on Exelixis once failed cancer drug FierceBiotech FDA approves cabozantinib for hepatocellular carcinoma U S Food and Drug Administration FDA 14 January 2019 Retrieved 23 September 2020 nbsp This article incorporates text from this source which is in the public domain Search of cabozantinib Recruiting Active not recruiting Enrolling by invitation Studies List Results ClinicalTrials gov clinicaltrials gov Retrieved 2021 08 09 Fisher MJ Shih CS Rhodes SD Armstrong AE Wolters PL Dombi E et al January 2021 Cabozantinib for neurofibromatosis type 1 related plexiform neurofibromas a phase 2 trial Nature Medicine 27 1 165 173 doi 10 1038 s41591 020 01193 6 PMC 8275010 PMID 33442015 Further reading editChoueiri TK Escudier B Powles T Mainwaring PN Rini BI Donskov F et al November 2015 Cabozantinib versus Everolimus in Advanced Renal Cell Carcinoma The New England Journal of Medicine 373 19 1814 1823 doi 10 1056 nejmoa1510016 PMC 5024539 PMID 26406150 External links edit Cabozantinib s malate NCI Drug Dictionary National Cancer Institute Cabozantinib S Malate National Cancer Institute 19 December 2012 Cabozantinib liver and kidney cancer MedlinePlus Clinical trial number NCT01835158 for Cabozantinib s malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer at ClinicalTrials gov Clinical trial number NCT01908426 for Study of Cabozantinib XL184 vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib CELESTIAL at ClinicalTrials gov Clinical trial number NCT03690388 for A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor VEGFR Targeted Therapy at ClinicalTrials gov Portal nbsp Medicine Retrieved from https en wikipedia org w index php title Cabozantinib amp oldid 1189528322, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.